People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...
GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
Earlier phases of the trial showed promising results, with a single 25mg dose of COMP360 psilocybin, combined with psychological support, significantly reducing depressive symptoms after three weeks, ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel mechanisms of action.
an inhalable treatment for treatment-resistant depression (TRD), demonstrating a significant placebo-adjusted reduction in depression scores as measured by the MADRS scale on Day 8. The trial ...
Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...
The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...